70 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/852982/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-852982 Apr 03, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates http://www.zacks.com/stock/news/853058/pharma-stock-roundup-jnj-snys-coronavirus-product-development-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-853058 Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Why the Earnings Surprise Streak Could Continue for Lilly (LLY) http://www.zacks.com/stock/news/857355/why-the-earnings-surprise-streak-could-continue-for-lilly-lly?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-857355 Apr 06, 2020 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes http://www.zacks.com/stock/news/857383/novo-nordisks-rybelsus-gets-eu-nod-for-type-ii-diabetes?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-857383 Apr 06, 2020 - Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-863161 Apr 09, 2020 - Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
Lilly Announces Clinical Study Plans for Coronavirus Disease http://www.zacks.com/stock/news/868591/lilly-announces-clinical-study-plans-for-coronavirus-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-868591 Apr 13, 2020 - Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month http://www.zacks.com/stock/news/871880/buy-5-top-stocks-set-to-beat-on-q1-earnings-this-month?cid=CS-ZC-FT-analyst_blog|investment_ideas-871880 Apr 15, 2020 - Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.
AstraZeneca to Begin Calquence Study for Coronavirus Treatment http://www.zacks.com/stock/news/872061/astrazeneca-to-begin-calquence-study-for-coronavirus-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-872061 Apr 15, 2020 - AstraZeneca (AZN) to initiate enrollment in a clinical study to evaluate its blood cancer drug, Calquence, as a potential treatment for patients hospitalized with COVID-19 infection.
Vanda Begins Enrollment in Study for Severe Coronavirus Infection http://www.zacks.com/stock/news/874470/vanda-begins-enrollment-in-study-for-severe-coronavirus-infection?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-874470 Apr 16, 2020 - Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/876251/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-876251 Apr 17, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?

Pages: 1234567

<<<Page 5>